Nine months after its introduction in the U.S., Eisai and Biogen’s Alzheimer’s drug Leqembi is encountering significant resistance in its widespread adoption, largely due to skepticism among some doctors about the efficacy of treating this degenerative brain disease. Preparation for an MRI scan – illustrative photo. Image credit: Accuray via Unsplash, free license Despite being […]
24 avril 2024
Aller à la source The European Times
Author: Newsdesk